Tarceva Gets Thumbs Down For NSCLC Maintenance As Cmte. Seeks Better Subgroup Analyses
This article was originally published in The Pink Sheet Daily
Executive Summary
ODAC expresses concern over OSI's use of "a single study with some design flaws showing very modest benefits."
You may also be interested in...
Will Maintenance Sell In NSCLC? Experts Weigh Costs Against Benefits
Longer-term "maintenance" therapy may be the new frontier for oncology products as cancer evolves into a chronic, manageable disease – a shift that will provide benefits for patients and the pharmaceutical industry. But as cancer drug costs continue to skyrocket and cost-effectiveness discussions become more commonplace, that transition may not come as smoothly as industry would like.
Will Maintenance Sell In NSCLC? Experts Weigh Costs Against Benefits
Longer-term "maintenance" therapy may be the new frontier for oncology products as cancer evolves into a chronic, manageable disease – a shift that will provide benefits for patients and the pharmaceutical industry. But as cancer drug costs continue to skyrocket and cost-effectiveness discussions become more commonplace, that transition may not come as smoothly as industry would like.
Astellas Wins OSI But Victory Comes At A Price
Japanese drug maker Astellas' painstaking pursuit of OSI Pharmaceuticals was rewarded on May 17 with a definitive merger agreement that has the unanimous support of both companies' boards